USA flag logo/image

An Official Website of the United States Government

BIODEGRADABLE INJECTABLE DELIVERY SYSTEM FOR NALTREXONE

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16813
Program Year/Program:
1991 / SBIR
Agency Tracking Number:
16813
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ATRIX LABORATORIES, INC.
2579 MIDPOINT DR Fort Collins, CO 80525
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1991
Title: BIODEGRADABLE INJECTABLE DELIVERY SYSTEM FOR NALTREXONE
Agency: HHS
Contract: N/A
Award Amount: $49,900.00
 

Abstract:

NALTREXONE IS AN EFFECTIVE NARCOTIC ANTAGONIST. HOWEVER, ITS EFFECTIVENESS IS LIMITED BY THE NEED FOR HIGH PATIENT COMPLIANCE, AS ORAL DOSAGES MUST BE TAKEN AT LEAST THREE TIMES WEEKLY. BY USING A PROPRIETARY DELIVERY SYSTEM, IT ISEXPECTED THAT NALTREXONE CAN BE DELIVERED AT A CONTROLLED RATE FOR ONE MONTH. THE DELIVERY SYSTEM TO STUDIED IS BIODEGRADABLE AND BIOCOMPATIBLE, AND HAS BEEN SHOWN TO CAUSENO ADVERSE TISSUE REACTIONS IN ANIMAL TESTING. IT HAS BEEN STUDIED IN VITRO FOR THE CONTROLLED RELEASE OF SEVERAL DRUGS AND IS CURRENTLY BEING STUDIED IN HUMANS UNDER A PHASEII IND. MOST IMPORTANTLY, IT CAN BE INJECTED USING STANDARDSYRINGES AND NEEDLES. NALTREXONE WILL BE INCORPORATED INTO THIS DELIVERY SYSTEM. THE EFFECT OF SEVERAL VARIABLES INCLUDING DRUG FORM AND POLYMER COMPOSITION, MOLECULAR WEIGHT AND CONCENTRATION, WILL BE STUDIED IN ORDER TO OBTAIN THE DESIRED RELEASE PROFILE OF 5 MG/DAY. THE MOST PROMISING FORMULATION WILL BETESTED IN RABBITS FOR TISSUE COMPATIBILITY. NALTREXONE IS AN EFFECTIVE NARCOTIC ANTAGONIST. HOWEVER, ITS EFFECTIVENESS IS LIMITED BY THE NEED FOR HIGH PATIENT COMPLIANCE, AS ORAL DOSAGES MUST BE TAKEN AT LEAST THREE TIMES WEEKLY. BY USING A PROPRIETARY DELIVERY SYSTEM, IT ISEXPECTED THAT NALTREXONE CAN BE DELIVERED AT A CONTROLLED RATE FOR ONE MONTH. THE DELIVERY SYSTEM TO STUDIED IS BIODEGRADABLE AND BIOCOMPATIBLE, AND HAS BEEN SHOWN TO CAUSENO ADVERSE TISSUE REACTIONS IN ANIMAL TESTING. IT HAS BEEN STUDIED IN VITRO FOR THE CONTROLLED RELEASE OF SEVERAL DRUGS AND IS CURRENTLY BEING STUDIED IN HUMANS UNDER A PHASEII IND. MOST IMPORTANTLY, IT CAN BE INJECTED USING STANDARDSYRINGES AND NEEDLES. NALTREXONE WILL BE INCORPORATED INTO THIS DELIVERY SYSTEM. THE EFFECT OF SEVERAL VARIABLES INCLUDING DRUG FORM AND POLYMER COMPOSITION, MOLECULAR WEIGHT AND CONCENTRATION, WILL BE STUDIED IN ORDER TO OBTAIN THE DESIRED RELEASE PROFILE OF 5 MG/DAY. THE MOST PROMISING FORMULATION WILL BETESTED IN RABBITS FOR TISSUE COMPATIBILITY.

Principal Investigator:

Arthur Tipton
3034825868

Business Contact:

Small Business Information at Submission:

Atrix Laboratories Inc
1625 Sharp Point Dr Box 20150 Fort Collins, CO 80522

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No